查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1796759

全球迟发性运动障碍药物市场报告：趋势、预测和竞争分析（至 2031 年）

Tardive Dyskinesia Treatment Medicine Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球迟发性运动障碍药物市场前景光明，医院和诊所市场蕴藏着巨大机会。预计2025年至2031年间，全球迟发性运动障碍药物市场规模将以4.5%的复合年增长率成长。该市场的主要驱动力是思觉失调症等疾病盛行率的上升，以及医疗服务提供者和患者意识的不断增强。

  • Lucintel 预测，在预测期内，Vmat2 抑制剂将达到最高的类型成长率。
  • 按用途类型来看，医院预计将实现高成长。
  • 按地区划分，预计亚太地区将在预测期内实现最高成长。

迟发性运动障碍治疗市场的新趋势

迟发性运动障碍药物的治疗前景正在迅速演变，一些新兴趋势正在影响全球疾病的治疗。这些趋势受到药物开发、数位医疗技术和以患者为中心的护理的推动，为改善迟发性运动障碍患者的治疗结果和生活品质创造了新的机会。

  • FDA认证核可药的采用率不断提升：FDA认证核可药，例如Valbenazine和Tetrabenazine，正在改变迟发性运动障碍的治疗方式。这些药物专门针对多巴胺系统，提供以症状为中心的治疗，且与传统药物相比副作用较少。这些药物的采用率不断提升，正在改善治疗效果和患者满意度，同时增强迟发性运动障碍的整体管理。随着更多治疗方法核准并进入市场，预计这一趋势将持续下去。
  • 个人化医疗的成长：个人化医疗是TD治疗市场的关键趋势，专注于根据患者的个别情况量身订做治疗方案。透过考虑遗传易感性、共病和疾病严重程度等因素，医疗保健提供者可以为每位患者选择最有效的治疗方法。这种方法在TD治疗中尤其重要，因为疾病严重程度和治疗反应存在个别差异。个人化医疗可望改善预后，并减少神经系统疾病治疗中常见的试验过程。
  • 数位健康工具的作用不断扩大：数位健康科技在迟发性运动障碍的管理中发挥越来越重要的作用。行动应用程式和远端医疗正在帮助临床医生远端监测患者的病情进展并即时调整治疗方案。数位工具也为患者提供了追踪症状的资源，从而提高了患者的参与度和对治疗计划的依从性。这些技术的持续进步将进一步改善对迟发性运动障碍患者的护理，并为治疗效果提供宝贵的见解。
  • 联合治疗的发展：联合治疗（即结合多种治疗方法）的趋势在迟发性运动障碍（TD）治疗市场中日益盛行。透过结合不同病症的药物，例如多巴胺受体拮抗剂和其他神经保护药物，患者可以获得更全面的症状缓解。联合治疗也正在临床试验中进行探索，并可能更好地控制迟发性运动障碍，尤其是在重症患者中。
  • 重视早期诊断和预防：早期诊断和介入是阻止迟发性运动障碍进展的关键。人们越来越重视透过先进的影像技术和早期筛检工具来提高诊断的准确性。早期疗育可以减轻症状的严重，有助于预防不可逆的残疾，并改善患者的长期预后。这一趋势得到了医疗保健提供者和患者权益组织的支持，他们致力于提高公众意识并鼓励积极治疗。

这些新兴趋势正在重塑迟发性运动障碍的治疗模式，提供更具针对性、个人化且更便利的治疗方案。随着新治疗方法和技术的不断发展，患者将有更好的症状管理机会，医疗保健系统也将能够提供更有效率、以患者为中心的照护。

迟发性运动障碍药物市场的最新发展

迟发性运动障碍治疗市场正在经历几项关键进展，这些进展正在推动创新，并改善受疾病影响患者的照护。这些进展的重点是提高治疗效果、满足未满足的需求以及扩大患者获得治疗的管道。

  • 新药核准：Valbenazine和Tetrabenazine等新药的核准彻底改变了迟发性运动障碍的治疗。这些药物特异性针对大脑中的多巴胺受体，抑制不自主运动，提供了比传统治疗方法更有效的治疗选择。这些药物的核准代表了迟发性运动障碍治疗方法的模式转移，为患者提供了更有效、更安全的选择。
  • 神经调节技术的进展：神经调节，包括深部脑部刺激 (DBS) 和经颅磁刺激 (TMS)，正在成为治疗方法。这些技术旨在改变大脑活动以缓解迟发性运动障碍的症状。研究神经调节疗效的临床试验已显示出良好的结果，并可能为对药物治疗无效的患者提供额外的治疗选择。
  • 基因治疗研究日益增加：基因治疗为迟发性运动障碍提供了潜在的长期解决方案。该领域的研究重点是开发针对迟发性运动障碍潜在遗传病因的治疗方法。虽然迟发性运动障碍的基因治疗仍处于早期阶段，但正在进行的研究正在探索其为此类神经系统疾病患者提供更有针对性、更有效治疗方案的潜力。
  • 诊断工具的改进：功能性磁振造影（MRI）和其他影像技术等诊断工具的进步，提高了早期发现迟发性运动障碍的能力。早期发现对于有效管理迟发性运动障碍至关重要，因为它可以及时干预，防止病情进展。诊断工具的改进提高了迟发性运动障碍诊断的准确性，使医疗保健提供者能够提供更好的照护。
  • 强调以患者为中心的照护：对于迟发性运动障碍患者，以患者为中心的照护日益受到重视。医疗保健提供者正在采用更全面的方法来管理迟发性运动障碍，不仅包括药物治疗，还包括生活方式介入、心理支持和患者教育。这种方法旨在提高迟发性运动障碍患者的整体生活质量，并根据他们的个人需求制定个人化治疗方案。

这些重大进展提高了迟发性运动障碍治疗的有效性和可近性。随着新药物、新技术和治疗策略的不断发展，迟发性运动障碍的治疗正变得更加个人化和有效，为患者带来更好的治疗效果。

目录

第一章执行摘要

第二章 市场概述

  • 背景和分类
  • 供应链

第三章：市场趋势与预测分析

  • 宏观经济趋势与预测
  • 产业驱动力与挑战
  • PESTLE分析
  • 专利分析
  • 法规环境

4. 全球迟发性运动障碍治疗市场（依类型）

  • 概述
  • 按类型分析吸引力
  • 囊泡单胺转运体 2 (Vmat2) 抑制剂：趋势与预测（2019-2031）
  • 肉毒桿菌：趋势与预测（2019-2031）
  • 其他：趋势与预测（2019-2031）

5. 全球迟发性运动障碍治疗市场（依应用）

  • 概述
  • 按用途分析吸引力
  • 医院：趋势与预测（2019-2031）
  • 医疗诊所：趋势与预测（2019-2031）
  • 其他：趋势与预测（2019-2031）

第六章区域分析

  • 概述
  • 全球迟发性运动障碍治疗市场（按地区）

7. 北美迟发性运动障碍治疗市场

  • 概述
  • 北美迟发性运动障碍治疗市场（按类型）
  • 北美迟发性运动障碍治疗市场（依应用）
  • 美国迟发性运动障碍治疗市场
  • 墨西哥迟发性运动障碍治疗市场
  • 加拿大迟发性运动障碍治疗市场

8.欧洲迟发性运动障碍药物市场

  • 概述
  • 欧洲迟发性运动障碍治疗市场（按类型）
  • 欧洲迟发性运动障碍治疗市场（依应用）
  • 德国迟发性运动障碍药物市场
  • 法国迟发性运动障碍治疗市场
  • 西班牙迟发性运动障碍治疗市场
  • 义大利迟发性运动障碍治疗市场
  • 英国迟发性运动障碍治疗市场

9. 亚太地区迟发性运动障碍治疗市场

  • 概述
  • 亚太地区迟发性运动障碍治疗市场（按类型）
  • 亚太地区迟发性运动障碍治疗市场（依应用）
  • 日本迟发性运动障碍治疗市场
  • 印度迟发性运动障碍治疗市场
  • 中国迟发性运动障碍治疗市场
  • 韩国迟发性运动障碍治疗市场
  • 印尼迟发性运动障碍治疗市场

10. 世界其他地区迟发性运动障碍治疗药物市场

  • 概述
  • 世界其他地区迟发性运动障碍治疗市场（按类型）
  • 世界其他地区迟发性运动障碍治疗市场（按应用）
  • 中东迟发性运动障碍治疗市场
  • 南美洲迟发性运动障碍治疗市场
  • 非洲迟发性运动障碍治疗市场

第十一章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析
    • 竞争对手之间的竞争
    • 买方的议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 新进入者的威胁
  • 市场占有率分析

第十二章机会与策略分析

  • 价值链分析
  • 成长机会分析
    • 按类型分類的成长机会
    • 按应用分類的成长机会
  • 全球迟发性运动障碍治疗市场的新趋势
  • 战略分析
    • 新产品开发
    • 认证和许可
    • 合併、收购、协议、合作和合资企业

第十三章：价值链主要企业概况

  • 竞争分析
  • Teva Pharmaceutical
  • Neurocrine Biosciences
  • Sun Pharmaceutical
  • SteriMax
  • Adamas Pharmaceuticals

第十四章 附录

  • 图表一览
  • 表格一览
  • 调查方法
  • 免责声明
  • 版权
  • 简称和技术单位
  • 关于 Lucintel
  • 询问

The future of the global tardive dyskinesia treatment medicine market looks promising with opportunities in the hospital and clinic markets. The global tardive dyskinesia treatment medicine market is expected to grow with a CAGR of 4.5% from 2025 to 2031. The major drivers for this market are the rising prevalence of conditions like schizophrenia and increased awareness among healthcare providers and patients.

  • Lucintel forecasts that, within the type category, Vmat2 inhibitors are expected to witness the highest growth over the forecast period.
  • Within the application category, hospitals are expected to witness higher growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Tardive Dyskinesia Treatment Medicine Market

The treatment landscape for tardive dyskinesia treatment medicine is rapidly evolving, with several emerging trends influencing how the condition is managed across the globe. These trends are shaped by advancements in drug development, digital health technologies, and patient-centered care, creating new opportunities for improving treatment outcomes and quality of life for those affected by TD.

  • Increased Adoption of FDA-Approved Medications: FDA-approved medications like valbenazine and deutetrabenazine are transforming the way tardive dyskinesia is treated. These drugs specifically target the dopamine system, offering targeted treatment for symptoms with fewer side effects compared to older medications. Their growing adoption is improving treatment outcomes and patient satisfaction while enhancing the overall management of TD. This trend is expected to continue as more treatments receive approval and enter the market.
  • Growth of Personalized Medicine: Personalized medicine is a key trend in the TD treatment market, focusing on tailoring therapies based on individual patient profiles. By considering factors such as genetic makeup, comorbidities, and disease severity, healthcare providers can select the most effective treatments for each patient. This approach is particularly important in the treatment of TD, as the condition varies in severity and response to treatment among individuals. Personalized medicine is likely to improve outcomes and reduce the trial-and-error process often associated with treating neurological disorders.
  • Expanding Role of Digital Health Tools: Digital health technologies are playing an increasingly important role in managing tardive dyskinesia. Mobile apps and telemedicine are helping doctors remotely monitor patient progress and adjust treatments in real-time. Digital tools also provide patients with resources to track their symptoms, improving engagement and adherence to treatment plans. As these technologies continue to improve, they will further enhance care delivery for individuals living with TD and provide valuable insights into treatment effectiveness.
  • Development of Combination Therapies: The trend toward combination therapies, where multiple treatment modalities are used together, is gaining momentum in the TD treatment market. By combining medications that target different aspects of the condition-such as dopamine receptor antagonists with other neuroprotective drugs-patients can achieve more comprehensive symptom relief. Combination therapies are also being explored in clinical trials, offering hope for better control of tardive dyskinesia, especially in patients with severe cases.
  • Increased Focus on Early Diagnosis and Prevention: Early diagnosis and intervention are crucial for preventing the progression of tardive dyskinesia. There is a growing emphasis on improving diagnostic accuracy through advanced imaging techniques and early screening tools. Early intervention can help reduce the severity of symptoms and prevent irreversible damage, thus enhancing the long-term prognosis for patients. This trend is being supported by healthcare providers and patient advocacy organizations that are working to raise awareness and encourage proactive care.

These emerging trends are reshaping the treatment landscape for tardive dyskinesia by offering more targeted, personalized, and accessible treatment options. As new therapies and technologies continue to develop, patients will have improved chances for better symptom management, and healthcare systems will be able to offer more efficient and patient-centered care.

Recent Developments in the Tardive Dyskinesia Treatment Medicine Market

The tardive dyskinesia treatment medicine market is witnessing several key developments, which are driving innovation and improving care for individuals affected by this condition. These developments are focused on enhancing treatment efficacy, addressing unmet needs, and expanding patient access to care.

  • Approval of New Medications: The approval of new medications like valbenazine and deutetrabenazine has significantly transformed the treatment of tardive dyskinesia. These drugs specifically target dopamine receptors in the brain to reduce involuntary movements, providing more effective treatment options than older therapies. Their approval has led to a paradigm shift in how TD is managed, offering patients more effective and safer options.
  • Advances in Neuromodulation Techniques: Neuromodulation, including deep brain stimulation (DBS) and transcranial magnetic stimulation (TMS), is gaining attention as a potential treatment for tardive dyskinesia. These techniques aim to regulate brain activity to alleviate symptoms of TD. Clinical trials investigating the efficacy of neuromodulation are showing promising results, which could expand treatment options for patients who do not respond to pharmacological therapies.
  • Increased Research in Gene Therapy: Gene therapy is emerging as a potential long-term solution for tardive dyskinesia. Research in this area is focused on developing treatments that can correct the underlying genetic causes of TD. Although gene therapy for TD is still in its early stages, ongoing studies are exploring its potential to offer more targeted and effective treatments for patients with this neurological disorder.
  • Improved Diagnostic Tools: Advances in diagnostic tools, such as functional MRI and other imaging techniques, are improving the ability to identify tardive dyskinesia in its early stages. Early detection is crucial for managing TD effectively, as it allows for timely intervention that can prevent the progression of the condition. Improved diagnostic tools are enhancing the accuracy of TD diagnoses and enabling healthcare providers to offer better care.
  • Focus on Patient-Centered Care: There is an increasing focus on patient-centered care for individuals with tardive dyskinesia. Healthcare providers are adopting more holistic approaches to managing TD, which include not only pharmacological treatment but also lifestyle interventions, psychological support, and patient education. This approach aims to improve the overall quality of life for TD patients and ensure that treatment plans are tailored to individual needs.

These key developments are enhancing the effectiveness and accessibility of treatments for tardive dyskinesia. As new medications, technologies, and treatment strategies continue to evolve, the management of TD is becoming more personalized and effective, leading to better outcomes for patients.

Strategic Growth Opportunities in the Tardive Dyskinesia Treatment Medicine Market

The tardive dyskinesia treatment medicine market offers numerous growth opportunities across key applications driven by technological advancements, increased awareness, and improved access to healthcare. Companies are focusing on innovative treatment strategies to address the unmet needs of patients and expand their market share.

  • Expansion of Novel Drug Therapies: The development of new drug therapies, including dopamine receptor antagonists and other innovative molecules, offers significant growth potential in the market. Pharmaceutical companies that invest in these treatments can capitalize on the increasing demand for more effective TD therapies, especially as new medications receive regulatory approval and enter the market.
  • Growth of Personalized Treatment Approaches: Personalized medicine, where treatments are tailored to individual patient profiles, presents a growth opportunity for the TD treatment market. By incorporating genetic testing and patient-specific factors, personalized approaches can lead to better treatment outcomes. This trend will become increasingly important as healthcare providers seek to provide more effective and individualized care.
  • Leveraging Digital Health Solutions: The integration of digital health solutions, such as telemedicine and mobile apps, into TD treatment offers significant growth opportunities. Digital health tools can assist in patient monitoring, symptom tracking, and providing real-time feedback, improving treatment adherence and patient engagement. These solutions are expected to become a key part of TD management strategies.
  • Market Expansion in Emerging Regions: Expanding access to treatment in emerging regions, such as Asia and Latin America, offers substantial growth opportunities for pharmaceutical companies. Rising healthcare infrastructure and increasing awareness of tardive dyskinesia are expected to drive demand for new treatments in these regions. Companies that can offer affordable and effective therapies will benefit from this growth.
  • Focus on Post-Treatment Care: The growing emphasis on post-treatment care, which includes patient support programs, ongoing monitoring, and rehabilitation, offers additional growth opportunities. Post-treatment care is essential for ensuring that patients maintain the benefits of their therapies and improve their long-term quality of life.

These strategic growth opportunities are shaping the future of the tardive dyskinesia treatment medicine market by driving innovation and expanding access to more effective and personalized treatments. Companies that capitalize on these trends will be well-positioned for success in the evolving TD treatment landscape.

Tardive Dyskinesia Treatment Medicine Market Driver and Challenges

The tardive dyskinesia treatment medicine market is influenced by several technological, economic, and regulatory factors. Understanding the key drivers and challenges is essential for navigating the market and developing effective solutions to address the needs of patients.

The factors responsible for driving the tardive dyskinesia treatment medicine market include:

1. Advances in Drug Development: The development of new drug therapies, including biologics and dopamine receptor antagonists, is driving growth in the market. These innovations provide more effective treatment options for TD, improving patient outcomes and expanding treatment choices.

2. Increased Awareness and Diagnosis: As awareness of tardive dyskinesia increases among healthcare providers and patients, earlier diagnosis and more timely interventions are leading to better management of the condition. This trend is expanding the market for TD treatments.

3. Rising Prevalence of Antipsychotic Use: The widespread use of antipsychotic medications, which are associated with tardive dyskinesia, is contributing to a higher prevalence of the condition. As more people are affected by TD, the demand for treatment options continues to rise.

4. Improved Regulatory Approvals: The faster regulatory approval processes for new treatments are allowing innovative therapies to reach the market more quickly, benefiting patients with tardive dyskinesia and driving market growth.

5. Focus on Personalized Treatment: Personalized treatment approaches, which consider individual patient needs, are improving the effectiveness of TD management. This trend is contributing to the growing demand for targeted therapies in the market.

Challenges in the tardive dyskinesia treatment medicine market are:

1. High Treatment Costs: The high cost of some of the newer medications, particularly biologics, is a major challenge for patients, especially in developing countries. These costs can limit access to treatment and hinder market growth.

2. Regulatory Barriers: Strict regulatory requirements and long approval timelines for new therapies can delay the introduction of innovative treatments, creating a barrier to market expansion.

3. Limited Awareness in Some Regions: In some regions, there is a lack of awareness about tardive dyskinesia, which can result in delayed diagnoses and treatment. This limits the market's potential in those areas.

The tardive dyskinesia treatment medicine market is shaped by advancements in drug development, increased awareness, and regulatory progress. However, challenges such as high treatment costs, regulatory barriers, and limited awareness in certain regions must be addressed to unlock the full potential of the market.

List of Tardive Dyskinesia Treatment Medicine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, tardive dyskinesia treatment medicine companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tardive dyskinesia treatment medicine companies profiled in this report include:

  • Teva Pharmaceutical
  • Neurocrine Biosciences
  • Sun Pharmaceutical
  • SteriMax
  • Adamas Pharmaceuticals

Tardive Dyskinesia Treatment Medicine Market by Segment

The study includes a forecast for the global tardive dyskinesia treatment medicine market by type, application, and region.

Tardive Dyskinesia Treatment Medicine Market by Type [Value from 2019 to 2031]:

  • Vesicular Monoamine Transporter 2 (Vmat2) Inhibitors
  • Botulinum Toxin
  • Others

Tardive Dyskinesia Treatment Medicine Market by Application [Value from 2019 to 2031]:

  • Hospital
  • Clinic
  • Others

Tardive Dyskinesia Treatment Medicine Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Tardive Dyskinesia Treatment Medicine Market

Tardive dyskinesia treatment medicine is a neurological condition characterized by involuntary, repetitive movements, often resulting from long-term use of antipsychotic medications. As the global incidence of TD rises due to the increased use of antipsychotics, there has been a notable shift towards developing more effective treatment options. Recent advances in treatment include the development of new medications and therapies that aim to reduce symptoms, improve patient quality of life, and minimize side effects. In countries like the United States, China, Germany, India, and Japan, the treatment landscape for tardive dyskinesia is evolving with new regulatory approvals, innovations, and increasing access to care.

  • United States: In the United States, there has been a significant focus on new medications for tardive dyskinesia. Recently approved drugs, such as valbenazine and deutetrabenazine, are now more widely prescribed, offering patients more effective options for managing symptoms. These medications work by targeting neurotransmitters in the brain, specifically dopamine receptors, to reduce involuntary movements. Additionally, there has been a rise in awareness and diagnostic efforts supported by advocacy organizations and healthcare initiatives. Ongoing clinical trials for newer treatments, including gene therapies and neuromodulation devices, are shaping the future landscape of TD treatment in the U.S.
  • China: China has seen a growing demand for tardive dyskinesia treatment due to the increasing use of antipsychotics, especially as mental health care access improves. While the treatment landscape remains somewhat limited compared to Western markets, there is a rising awareness of TD. Chinese healthcare providers are adopting newer medications that have been successful internationally, such as deutetrabenazine, though the availability of these drugs is still inconsistent across the country. Furthermore, local pharmaceutical companies are investing in the research and development of TD treatments, indicating future growth and more localized solutions in the coming years.
  • Germany: Germany is witnessing considerable advancements in the treatment of tardive dyskinesia, with new drugs entering the market, such as valbenazine. The German healthcare system is well-equipped to handle specialized treatments, and regulatory approval processes for new therapies are relatively streamlined. The market is also benefiting from strong research collaborations and clinical trials that focus on improving therapeutic outcomes for patients with TD. Additionally, Germany is embracing digital health tools that can assist in monitoring patients and tailoring individualized treatment plans, helping doctors manage this complex condition more effectively.
  • India: In India, tardive dyskinesia treatment is gaining more attention as the number of people receiving antipsychotic medications increases. However, access to new and advanced treatments for TD remains limited due to challenges with cost and availability. While traditional treatments like anticholinergics are still in use, newer medications, such as valbenazine, are slowly becoming available, though they are often out of reach for lower-income populations. Healthcare initiatives, along with increased awareness, are gradually improving diagnosis rates and encouraging early intervention. Growth in the Indian market is expected as healthcare infrastructure and access to modern medications improve.
  • Japan: Japan is one of the leading countries in terms of advancements in medical technology and drug approval for tardive dyskinesia. The country has seen increased adoption of drugs like deutetrabenazine and valbenazine, both of which have proven effective in reducing symptoms of TD. Japan's regulatory process is relatively efficient, allowing for quick access to cutting-edge treatments. Furthermore, Japan is exploring the potential of innovative treatments such as gene therapy and neuromodulation, offering hope for more targeted and effective solutions for managing tardive dyskinesia in the future.

Features of the Global Tardive Dyskinesia Treatment Medicine Market

  • Market Size Estimates: Tardive dyskinesia treatment medicine market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Tardive dyskinesia treatment medicine market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Tardive dyskinesia treatment medicine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the tardive dyskinesia treatment medicine market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tardive dyskinesia treatment medicine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the tardive dyskinesia treatment medicine market by type (vesicular monoamine transporter 2 (Vmat2) inhibitors, botulinum toxin, and others), application (hospital, clinic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Tardive Dyskinesia Treatment Medicine Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Vesicular Monoamine Transporter 2 (Vmat2) Inhibitors: Trends and Forecast (2019-2031)
  • 4.4 Botulinum Toxin: Trends and Forecast (2019-2031)
  • 4.5 Others: Trends and Forecast (2019-2031)

5. Global Tardive Dyskinesia Treatment Medicine Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Hospital: Trends and Forecast (2019-2031)
  • 5.4 Clinic: Trends and Forecast (2019-2031)
  • 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Tardive Dyskinesia Treatment Medicine Market by Region

7. North American Tardive Dyskinesia Treatment Medicine Market

  • 7.1 Overview
  • 7.2 North American Tardive Dyskinesia Treatment Medicine Market by Type
  • 7.3 North American Tardive Dyskinesia Treatment Medicine Market by Application
  • 7.4 United States Tardive Dyskinesia Treatment Medicine Market
  • 7.5 Mexican Tardive Dyskinesia Treatment Medicine Market
  • 7.6 Canadian Tardive Dyskinesia Treatment Medicine Market

8. European Tardive Dyskinesia Treatment Medicine Market

  • 8.1 Overview
  • 8.2 European Tardive Dyskinesia Treatment Medicine Market by Type
  • 8.3 European Tardive Dyskinesia Treatment Medicine Market by Application
  • 8.4 German Tardive Dyskinesia Treatment Medicine Market
  • 8.5 French Tardive Dyskinesia Treatment Medicine Market
  • 8.6 Spanish Tardive Dyskinesia Treatment Medicine Market
  • 8.7 Italian Tardive Dyskinesia Treatment Medicine Market
  • 8.8 United Kingdom Tardive Dyskinesia Treatment Medicine Market

9. APAC Tardive Dyskinesia Treatment Medicine Market

  • 9.1 Overview
  • 9.2 APAC Tardive Dyskinesia Treatment Medicine Market by Type
  • 9.3 APAC Tardive Dyskinesia Treatment Medicine Market by Application
  • 9.4 Japanese Tardive Dyskinesia Treatment Medicine Market
  • 9.5 Indian Tardive Dyskinesia Treatment Medicine Market
  • 9.6 Chinese Tardive Dyskinesia Treatment Medicine Market
  • 9.7 South Korean Tardive Dyskinesia Treatment Medicine Market
  • 9.8 Indonesian Tardive Dyskinesia Treatment Medicine Market

10. ROW Tardive Dyskinesia Treatment Medicine Market

  • 10.1 Overview
  • 10.2 ROW Tardive Dyskinesia Treatment Medicine Market by Type
  • 10.3 ROW Tardive Dyskinesia Treatment Medicine Market by Application
  • 10.4 Middle Eastern Tardive Dyskinesia Treatment Medicine Market
  • 10.5 South American Tardive Dyskinesia Treatment Medicine Market
  • 10.6 African Tardive Dyskinesia Treatment Medicine Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Tardive Dyskinesia Treatment Medicine Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Teva Pharmaceutical
    • Company Overview
    • Tardive Dyskinesia Treatment Medicine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Neurocrine Biosciences
    • Company Overview
    • Tardive Dyskinesia Treatment Medicine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Sun Pharmaceutical
    • Company Overview
    • Tardive Dyskinesia Treatment Medicine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 SteriMax
    • Company Overview
    • Tardive Dyskinesia Treatment Medicine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Adamas Pharmaceuticals
    • Company Overview
    • Tardive Dyskinesia Treatment Medicine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Tardive Dyskinesia Treatment Medicine Market
  • Figure 2.1: Usage of Tardive Dyskinesia Treatment Medicine Market
  • Figure 2.2: Classification of the Global Tardive Dyskinesia Treatment Medicine Market
  • Figure 2.3: Supply Chain of the Global Tardive Dyskinesia Treatment Medicine Market
  • Figure 2.4: Driver and Challenges of the Tardive Dyskinesia Treatment Medicine Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 4.1: Global Tardive Dyskinesia Treatment Medicine Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Tardive Dyskinesia Treatment Medicine Market ($B) by Type
  • Figure 4.3: Forecast for the Global Tardive Dyskinesia Treatment Medicine Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Vesicular Monoamine Transporter 2 (Vmat2) Inhibitors in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Botulinum Toxin in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Figure 4.6: Trends and Forecast for Others in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Figure 5.1: Global Tardive Dyskinesia Treatment Medicine Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Tardive Dyskinesia Treatment Medicine Market ($B) by Application
  • Figure 5.3: Forecast for the Global Tardive Dyskinesia Treatment Medicine Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Hospital in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Clinic in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Others in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Figure 6.1: Trends of the Global Tardive Dyskinesia Treatment Medicine Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Tardive Dyskinesia Treatment Medicine Market ($B) by Region (2025-2031)
  • Figure 7.1: Trends and Forecast for the North American Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Figure 7.2: North American Tardive Dyskinesia Treatment Medicine Market by Type in 2019, 2024, and 2031
  • Figure 7.3: Trends of the North American Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2019-2024)
  • Figure 7.4: Forecast for the North American Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2025-2031)
  • Figure 7.5: North American Tardive Dyskinesia Treatment Medicine Market by Application in 2019, 2024, and 2031
  • Figure 7.6: Trends of the North American Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2019-2024)
  • Figure 7.7: Forecast for the North American Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2025-2031)
  • Figure 7.8: Trends and Forecast for the United States Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Mexican Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 7.10: Trends and Forecast for the Canadian Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 8.1: Trends and Forecast for the European Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Figure 8.2: European Tardive Dyskinesia Treatment Medicine Market by Type in 2019, 2024, and 2031
  • Figure 8.3: Trends of the European Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2019-2024)
  • Figure 8.4: Forecast for the European Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2025-2031)
  • Figure 8.5: European Tardive Dyskinesia Treatment Medicine Market by Application in 2019, 2024, and 2031
  • Figure 8.6: Trends of the European Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2019-2024)
  • Figure 8.7: Forecast for the European Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2025-2031)
  • Figure 8.8: Trends and Forecast for the German Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the French Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Spanish Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the Italian Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 8.12: Trends and Forecast for the United Kingdom Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 9.1: Trends and Forecast for the APAC Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Figure 9.2: APAC Tardive Dyskinesia Treatment Medicine Market by Type in 2019, 2024, and 2031
  • Figure 9.3: Trends of the APAC Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2019-2024)
  • Figure 9.4: Forecast for the APAC Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2025-2031)
  • Figure 9.5: APAC Tardive Dyskinesia Treatment Medicine Market by Application in 2019, 2024, and 2031
  • Figure 9.6: Trends of the APAC Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2019-2024)
  • Figure 9.7: Forecast for the APAC Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2025-2031)
  • Figure 9.8: Trends and Forecast for the Japanese Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Indian Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the Chinese Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the South Korean Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 9.12: Trends and Forecast for the Indonesian Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 10.1: Trends and Forecast for the ROW Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Figure 10.2: ROW Tardive Dyskinesia Treatment Medicine Market by Type in 2019, 2024, and 2031
  • Figure 10.3: Trends of the ROW Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2019-2024)
  • Figure 10.4: Forecast for the ROW Tardive Dyskinesia Treatment Medicine Market ($B) by Type (2025-2031)
  • Figure 10.5: ROW Tardive Dyskinesia Treatment Medicine Market by Application in 2019, 2024, and 2031
  • Figure 10.6: Trends of the ROW Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2019-2024)
  • Figure 10.7: Forecast for the ROW Tardive Dyskinesia Treatment Medicine Market ($B) by Application (2025-2031)
  • Figure 10.8: Trends and Forecast for the Middle Eastern Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the South American Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 10.10: Trends and Forecast for the African Tardive Dyskinesia Treatment Medicine Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Tardive Dyskinesia Treatment Medicine Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Tardive Dyskinesia Treatment Medicine Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Tardive Dyskinesia Treatment Medicine Market by Type
  • Figure 12.2: Growth Opportunities for the Global Tardive Dyskinesia Treatment Medicine Market by Application
  • Figure 12.3: Growth Opportunities for the Global Tardive Dyskinesia Treatment Medicine Market by Region
  • Figure 12.4: Emerging Trends in the Global Tardive Dyskinesia Treatment Medicine Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Tardive Dyskinesia Treatment Medicine Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Tardive Dyskinesia Treatment Medicine Market by Region
  • Table 1.3: Global Tardive Dyskinesia Treatment Medicine Market Parameters and Attributes
  • Table 3.1: Trends of the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 3.2: Forecast for the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Tardive Dyskinesia Treatment Medicine Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 4.4: Trends of Vesicular Monoamine Transporter 2 (Vmat2) Inhibitors in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 4.5: Forecast for Vesicular Monoamine Transporter 2 (Vmat2) Inhibitors in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 4.6: Trends of Botulinum Toxin in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 4.7: Forecast for Botulinum Toxin in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 4.8: Trends of Others in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 4.9: Forecast for Others in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Tardive Dyskinesia Treatment Medicine Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 5.4: Trends of Hospital in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 5.5: Forecast for Hospital in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 5.6: Trends of Clinic in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 5.7: Forecast for Clinic in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 5.8: Trends of Others in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 5.9: Forecast for Others in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 7.1: Trends of the North American Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 7.2: Forecast for the North American Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 8.1: Trends of the European Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 8.2: Forecast for the European Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Type in the European Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Type in the European Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the European Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the European Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 9.1: Trends of the APAC Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 9.2: Forecast for the APAC Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 10.1: Trends of the ROW Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 10.2: Forecast for the ROW Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Tardive Dyskinesia Treatment Medicine Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Tardive Dyskinesia Treatment Medicine Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Tardive Dyskinesia Treatment Medicine Market (2019-2031)
  • Table 11.1: Product Mapping of Tardive Dyskinesia Treatment Medicine Suppliers Based on Segments
  • Table 11.2: Operational Integration of Tardive Dyskinesia Treatment Medicine Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Tardive Dyskinesia Treatment Medicine Revenue
  • Table 12.1: New Product Launches by Major Tardive Dyskinesia Treatment Medicine Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Tardive Dyskinesia Treatment Medicine Market